{
    "eid": "2-s2.0-84924081603",
    "title": "A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma",
    "cover-date": "2015-03-01",
    "subject-areas": [
        {
            "$": "Hematology",
            "@code": "2720"
        }
    ],
    "keywords": [
        "Belinostat",
        "Histone deacetylase inhibitors",
        "Mycosis fungoides",
        "Peripheral T cell Lymphoma",
        "T cell lymphoma"
    ],
    "authors": [
        "Francine Foss"
    ],
    "citedby-count": 170,
    "ref-count": 30,
    "ref-list": [
        "New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes",
        "Rational combinations using HDAC inhibitors",
        "The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications",
        "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas",
        "Revised response criteria for malignant lymphoma",
        "Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy",
        "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: Multinational phase II-III trial results",
        "Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma",
        "A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia",
        "The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.",
        "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors",
        "A phase i study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours",
        "Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification",
        "Histone deacetylase inhibitors: Current status and overview of recent clinical trials",
        "Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma",
        "Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study",
        "Novel therapies in peripheral T-cell lymphomas",
        "Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma",
        "Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells",
        "Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101",
        "Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma",
        "Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study",
        "Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies",
        "Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the non-Hodgkin's lymphoma classification project",
        "A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors",
        "Quantifying skin disease burden in mycosis fungoides-type cutaneous t-cell lymphomas: The severity-weighted assessment tool (SWAT)",
        "International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes international T-cell lymphoma project",
        "Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma",
        "WHO-EORTC classification for cutaneous lymphomas"
    ],
    "affiliation": [
        {
            "affiliation-city": "Boston",
            "affilname": "Spectrum Pharmaceuticals, Inc.",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bordeaux",
            "affilname": "Universit\u00e9 de Bordeaux",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Cleveland",
            "affilname": "Taussig Cancer Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New Haven",
            "affilname": "Yale Cancer Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "affilname": "New York University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Toulouse",
            "affilname": "H\u00f4pital Purpan",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Houston",
            "affilname": "The University of Texas MD Anderson Cancer Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Dana-Farber Cancer Institute",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Stanford",
            "affilname": "Stanford University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Essen",
            "affilname": "Universit\u00e4tsklinikum Essen",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Tel Aviv-Yafo",
            "affilname": "Tel Aviv University",
            "affiliation-country": "Israel"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Boston Medical Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Jerusalem",
            "affilname": "Hadassah University Medical Centre",
            "affiliation-country": "Israel"
        },
        {
            "affiliation-city": "Copenhagen",
            "affilname": "Topotarget",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Songkla",
            "affilname": "Songlanagarind Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kansas City",
            "affilname": "Kansas City Cancer Center",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}